Exploring Translational Strategies to Combat Antibiotic Resistance – Appendix 1

Translational Strategies to Combat Antibiotic Resistance: “A Call to Action”

February 6-7, 2013
Canada House, London, UK

Participants List

Name and Organization Background

Danny Altmann
Head of Pathogens, Immunology and Population Health
The Wellcome Trust

6th Feb only

  • Basic HLA, T cell receptor and NK cell immunology
  • Virology research including herpes viruses and HIV and emphasis on the development of transgenic disease models
  • Immunology of bacterial sepsis and the immunopathogenesis of multiple sclerosis

Keith Barker
Medical Director, Infectious Diseases Therapy Area Unit,

  • Anti-infective late-stage drug development
  • Current focus is with novel mode of action antibiotics
  • Currently clinical lead for GSK in the IMI ND4BB project
  • Previously worked in fields of malaria and chronic hepatitis B & C
  • Before GSK worked with the UK HPA and MHRA

Judy Bray
Assistant Director
CIHR Institute of Infection and Immunity
Canadian Institutes of Health Research, Ottawa, Canada

Workshop Organizing Committee

Eric Brown
Chair, Department of Biochemistry and Biomedical Sciences
McMaster University, Hamilton, Ontario

  • Complex and poorly understood aspects of biology in bacteria using molecular genetic and biochemical approaches
  • Cell wall and ribosome biogenesis
  • Chemical genomics aimed at mapping and understanding the interaction of drug-like small molecules with bacterial cell systems

Elizabeth Bryce
Clinical professor and Regional Medical Director for Infection Control at Vancouver Coastal Health

  • Antimicrobial resistance and its Infection Control Aspects
  • Sterilization and Disinfection
  • Infectious Diseases and emerging Infectious Diseases
  • Infection Control Education
  • Infection Control Workplace Assessment and Program Development Surveillance

Anthony Clarke
Professor, Assistant VP (Graduate Studies & Program Quality Assurance)
University of Guelph, Guelph, Ontario

  • Structure and function relationship of enzymes involved in the metabolism of the bacterial cell wall polymer peptidoglycan, and the biodegradation of cellulose
  • Identifying new potential targets for antibiotic development
Anthony is the Co-PI of one of the teams funded under the Canada/UK partnership on AMR

Anthony Coates
Prof. of Medical Microbiology,
St George's University, London;
Founder of Helperby Therapeutics

  • Tuberculosis
  • Non-multiplying bacteria, dormant bacteria, stationary phase bacteria
  • Latent infection
  • Antibiotics
  • Chaperonins

John Conly
Professor of Medicine, Microbiology, Immunology and Infectious Diseases,
Centre for Antimicrobial Resistance,
Co-Director, Synder Institute for Chronic Diseases,
University of Calgary

  • Antimicrobial resistance
  • Prevention of hospital infections
  • Optimal antimicrobial utilization
  • Policy development in the area of antimicrobial stewardship
  • Development of innovative tools in healthcare delivery
Founder, Ward of the 21st Century

Lloyd Czaplewski
Director, Chemical Biology Ventures;
Founder & Director, Abgentis Ltd &
Member, MRC Infection and Immunity Board

  • 20-years biotech R&D experience “Concept to Clinic”
  • DNA Supercoiling inhibitors (GyrB/ParE)
  • Fundraising (>£22m to date)
  • Business development (Deals worth >$100m in upfront, milestones & royalties)
  • Chemical Biology Ventures Ltd: life sciences translational R&D Consultancy
  • Abgentis Limited: Re-engineering novobiocin to create a broad-spectrum IV/Oral antibiotic to treat skin and skin structure infections, community-acquired bacterial pneumonia and sexually transmitted bacterial diseases

Chris Dowson
Professor of Microbiology
University of Warwick

  • Characterization of key biochemical pathways present across a diverse range of human and animal pathogens
  • Re-exploration of peptidoglycan biosynthesis – the structural polymer of bacterial cell walls – for drug discovery
Chris is the Co-PI of one of the teams funded under the Canada/UK partnership on AMR

Edie Dullaghan
Head, Target validation
Centre for Drug Research and Development (CDRD)
Vancouver, British Columbia

The Centre for Drug Research and Development (CDRD) is Canada’s fully-integrated national drug development and commercialization centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising earlystage drug candidates. Its mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR)

Rainer Engelhardt
Assistant Deputy Minister, Infectious Disease Prevention and Control
Public Health Agency of Canada
Ottawa, Canada

  • Development of federal legislation and environmental regulation
  • Management of large-scale national and international industry-government science and technology programs in Canada and the United States
  • Biomedical physiology
  • Prevention and control of infectious diseases, including antimicrobial resistance and development of biopharmaceutical products alternative to antibiotics

Diane Gosselin
President and CEO,
The Québec Consortium for Drug Discovery (CQDM)

CQDM is a non-profit organization whose mission is to identify, fund and support research projects conducted jointly by university teams and groups from the private sector in biopharmaceutical research. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process. CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry.

Robert (Bob) Hancock
Department of Microbiology and Immunology
University of British Columbia

  • Mechanism of action of cationic host defence (antimicrobial) peptides and their role as modulators of innate immunity (including basic functional genomic studies to define the innate immunity network)
  • Novel therapeutics based on the immunomodulatory and antibiotic activities of host defence peptides
  • Functional genomics of the nosocomial pathogen, Pseudomonas aeruginosa, with reference to antibiotic resistance and the regulation of resistance and virulence

David Harper
Chief Scientific Officer
AmpliPhi Biosciences

6th Feb only

  • Antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform
  • Gram negative bacterial infections that are often resistant to existing antibiotic treatments
  • Product development opportunities to combine bacteriophage-based therapeutics with conventional antibiotics and develop multi-target, indication-specific therapeutics through the application of its bacteriophage technology and its established and expanding phage bank applicable to a range of bacterial targets

David Heymann
UK Health Protection Agency

6th Feb only

  • Development of a global framework for the control of antimicrobial resistance,
  • Emerging and other Communicable Diseases
  • Medical epidemiology
  • Public health
  • Global health
  • Malaria and other tropical infections

Rebecca Hodges
Programme Manager, Infections and Immunity
Medical Research Council

Dr Rebecca Hodges is the programme manager for general infections at the UK Medical Research Council. Rebecca manages the MRC’s portfolio of research on infectious disease and strategic investments in the area, including AMR.

Katie Hopkins
Clinical Scientist, Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI),
Health Protection Agency,

  • Molecular mechanisms and epidemiology of antimicrobial resistant organisms
  • Application of novel genotypic and phenotypic methods for the rapid detection of AMR

Richard Jarvest
Senior Scientific Director,
Infectious Diseases and Diseases of the Developing World
Business Development

  • Anti-infective drug discovery from target to candidate
  • Targets and chemical classes for antibacterial agents against antibiotic-resistant bacteria
  • Establishing and managing GSK-biotech drug discovery collaborations in infectious diseases

Malcolm Kendall
CEO and Director
Indel Therapeutics Inc.
Vancouver, British Columbia

Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficultto- treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.

Debbie Laubach
Operations Manager

Debbie oversees all research, events organisation, and advisory groups within MediWales. Debbie has spent the past five years forming professional relationships with clinical, academic and industry stakeholders and assisting collaboration between them.

Caroline Martin
Manager, Science & Innovation Programme
High Commission of Canada,
London, UK

Workshop Organizing Committee

David McIntosh
Global Scientific Affairs Expert,
Novartis Vaccines & Diagnsotics
Honorary Clinical Senior Lecturer, Department of Medicine, Imperial College

6th Feb only

  • Pediatrics
  • Vaccines
  • Infectious diseases

Howard Njoo
Director General of the Centre for Communicable Diseases and Infection Control
Public Health Agency of Canada

  • Public Health
  • Risk Assessment
  • Risk Management for the Prevention and Control of Tuberculosis
  • Antimicrobial resistance
  • Infection control

Seamus O’Brien
TA Clinical Director, Global Clinical Infection

  • Therapeutic Area Clinical Director and Operations and Strategy lead for AZ’s Infection Global Medicines Unit
  • Antibiotics and biologics for the treatment and prevention of serious bacterial infections
  • Clinical development of antibiotics for the prevention & treatment of resistant bacterial infections

Marc Ouellette
Scientific Director
CIHR Institute of Infection and Immunity
Université Laval
Québec City

  • Antimicrobial resistance
  • Mechanisms of resistance in the parasite, Leishmania and the bacteria Streptococcus pneumoniae
  • Development of new tools to diagnose resistance and novel targets for new drugs; novel pathways; potential therapeutic and diagnostic targets; phage therapy; whole genome analysis

Thomas Parr
President and CEO
Fedora Pharmaceuticals Inc

  • Discovery and development of novel antibiotics targeting life-threatening microbial drug resistance
  • β-Lactamase inhibitors with potent activity against highly resistant bacterial strains including the newly emerging metallo-β- lactamase NDM-1

Charles Penn
Coordinator, Pandemic and Epidemic Diseases,
World Health Organisation

7th Feb only

  • Use of antivirals in influenza management
  • Antimicrobial resistance
  • Infection prevention and control
  • Hepatitis and respiratory viruses
  • Vaccine research and development
  • Epidemic and intervention modelling in infectious diseases

Mair Powell
Chair, EMA Infectious Disease Working Party

7th Feb only

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe. The MHRA is an executive agency of the Department of Health. The European Medicines Agency's (EMA) is responsible for the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.

Jennifer Raven
Associate, Strategic Initiatives
CIHR Institute of Infection and Immunity
Université Laval, Québec City

Workshop Organizing Committee

David Rhodes
Director of Business Development
UK Health Protection Agency

7th Feb only

David Rhodes is Head of Business Development for the Health Protection Agency and a Deputy Director in the Finance and Resource Division of HPA. He is responsible for the external business activities of HPA, where infectious disease, including antimicrobial resistance, forms a key element in the business portfolio. Responsibilities include commercial strategy and policy, intellectual property management, negotiation of R&D and scientific services contracts, and marketing, both in the UK and globally.

Mitch Rogers
Business Development Manager
UK Health Protection Agency

Workshop Organizing Committee

David Roper
Associate Professor of Structural Biology,
School of Life Sciences University of Warwick

  • Antibiotic Resistance Mechanisms
  • Bacterial Cell Wall Biosynthesis
  • Bacterial Cell Division
  • Bioremediation and Degradation of Aromatic Chemicals.
  • Antimicrobial Drug Discovery

Nigel Silman
Strategic Co-ordinator, Research UK Health Protection Agency;
Visiting Professor of Infectious Diseases, University of the West of England

Workshop Organizing Committee

Natalie Strynadka
Professor, Biochemistry and Molecular Biology, Medicine; and
Associate Member, Michael Smith Laboratories

  • Structural and mechanistic characterization of membrane associated assemblies as targets for antibiotic and vaccine development
  • Structure-based design of novel, therapeutically useful antibiotics and inhibitors of antibiotic-resistance mechanisms
  • X-ray crystallography, NMR, EM, mass spectrometry, molecular modeling, molecular docking and molecular biology
Natalie is the Co-PI of one of the teams funded under the Canada/UK partnership on AMR

Jim Spencer
Lecturer in Microbial Pathogenesis,
University of Bristol

  • Structure-based design of novel antimicrobials, Application of rapid kinetic and crystallographic methods to study of the structure, mechanism and inhibition of both serine and metallo-beta-lactamases
  • Molecular mechanisms by which resistance arises to a number of other antibiotic classes including the quinlones and oxazolidinones (Qnr and Cfr proteins, respectively)

Peter Taylor
Professor of Microbiology,
University College London, School of Pharmacy

  • New approaches to the treatment of bacterial infections, particularly in relation to reversible modification of the bacterial phenotype
  • Natural products with antibacterial activity
  • Impact of the space environment on the staphylococcal phenotype
  • New DNA-interactive drugs

Nick Taylor
Epidemiology and Risk Team Leader
UK Centre for Environment Fisheries and Aquaculture Science (Cefas)
Weymouth Laboratory

  • Epidemiology
  • Population Dynamics
  • Pathogen control
  • Environmental reservoirs of AMR
  • Modelling the acquisition and persistence of AMR
  • Risk assessment of AMR dissemination pathways

David Verner-Jeffreys
Senior Microbiologist,
UK Centre for Environment Fisheries and Aquaculture Science (Cefas)
Weymouth Laboratory

  • Aquatic animal health
  • Development of sustainable aquaculture
  • Aquatic animal health product development and testing
  • Antibiotic resistance in pathogens of fish and shellfish
  • Monitoring aquatic environmental reservoirs of resistance
  • Member of the UK's Department for Environment Food and Rural affairs (Defra) Antimicrobial Resistance Committee (DARC)

John Wain
Prof in Medical Microbiology,
University of East Anglia and
CSO, Discuva Ltd

  • Genetic diversity in antibiotic resistant bacteria,
  • Translation of basic science research into public health-relevant tools.

Des Walsh
Head, Infections and Immunity,
Lead for Stratified Medicine Medical Research Council
desmond.walsh@headoffice.mrc. ac.uk

7th Feb only

Dr Des Walsh is Head of Infections and Immunity and Lead for Stratified Medicine at the UK Medical Research Council. Des is responsible for shaping and developing the Infections and Immunity portfolio, developing and implementing strategy and collaborative activities in the area.

Sally Wellsteed
Team Leader Infection Control,
Infectious Diseases and Blood Policy Branch
UK Department of Health

  • Healthcare associated antimicrobial resistance

David Williams
CEO, Discuva Ltd

  • Drug discovery in Pharma/Biotech including infectious disease - small molecule antibiotics to any bacteria.
  • Identification of molecular target(s) and any potential resistance mechanisms.
  • Prioritisation of compound series for hit-to-lead chemistry.
  • Rapid point-of-care diagnostics

Angela Wittelsberger
Scientific Officer
Innovative Medicines Initiative,
Brussels, Belgium

The Innovative Medicines Initiative (IMI) is the largest public-private partnership in life sciences. In 2012, IMI launched the New Drugs for Bad Bugs (ND4BB) programme, as a result of the EU Action plan against the rising threats from Antimicrobial Resistance. In an unprecedented € 348M effort, IMI’s first three projects under the ND4BB programme aim to improve clinical trials for new antibiotics, to increase our understanding of penetration into and efflux out of Gram-negative bacteria, and to push novel antibiotic discovery programmes from the academic and SME sector into clinical development.

Gerard (Gerry) Wright
Director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster;
Professor, Department of Biochemistry and Biomedical Sciences;
founding director of the McMaster Antimicrobial Research Centre

  • Genomic Enzymology to study antibiotic resistance.
  • Mechanisms of Antibiotic Resistance
  • Reversing Resistance with Small
  • Origins, Evolution and Sources of Resistance
Date modified: